Cited time in webofscience Cited time in scopus

Full metadata record

DC Field Value Language
dc.contributor.author Khan, lImran ko
dc.contributor.author Bhardwaj, Monika ko
dc.contributor.author Shukla, Shruti ko
dc.contributor.author Lee, Hoomin ko
dc.contributor.author Oh, Mi-Wah ko
dc.contributor.author Bajpai, Vivek K. ko
dc.contributor.author Huh, Yun Suk ko
dc.contributor.author Kang, Sun Chul ko
dc.date.accessioned 2019-07-11T09:05:54Z -
dc.date.available 2019-07-11T09:05:54Z -
dc.date.created 2019-07-01 -
dc.date.issued 2019-09 -
dc.identifier.citation Colloids and Surfaces B: Biointerfaces, v.181, pp.612 - 622 -
dc.identifier.issn 0927-7765 -
dc.identifier.uri http://hdl.handle.net/20.500.11750/10124 -
dc.description.abstract Nanoemulsion-based synthesis has been introduced to enhance the bioavailability of natural compounds at target sites for their various biomedical applications. In this study, we synthesized carvacrol nanoemulsion (CN) an oil-in-water (O/W) as a nano-emulsion vehicle system by using ultrasonication emulsification for anti-angiogenesis therapy formulated by combining MCT, lecithin, and polysorbate 80 at the O/W interface called carvacrol encapsulated nanoemulsion (CEN). The diameter of CEN determined by TEM analysis was 105.32 nm. The hydrodynamic droplet size was 101.0 nm with a -39.38-mV zeta potential. The stability of the synthesized CEN was approved till 100 days without any change in diameter size distribution and encapsulation efficiency. We evaluated the role of CEN on angiogenesis in lung adenocarcinoma A549 cells both in vitro and in vivo and observed that it reduced the growth and MMP levels of A549 cells in a dose-dependent manner. Exposure to CEN decreased the activation of MAPK p38 as well as ERK. Moreover, we found that CEN reduced the expression of VEGF and CD31 in A549 cells both in vitro and in vivo. Our in-silico study also indicated the binding of carvacrol to COX-2 and VEGF at the active and allosteric sites of CD31 with low binding energy. Overall, CEN induced anti-angiogenic effects in A549 cells in vitro, in silico, and in vivo, thereby establishing its potential as targeted drug delivery vehicle against angiogenesis. © 2019 Elsevier B.V. -
dc.language English -
dc.publisher Elsevier BV -
dc.title Carvacrol encapsulated nanocarrier/ nanoemulsion abrogates angiogenesis by downregulating COX-2, VEGF and CD31 in vitro and in vivo in a lung adenocarcinoma model -
dc.type Article -
dc.identifier.doi 10.1016/j.colsurfb.2019.06.016 -
dc.identifier.wosid 000481565300071 -
dc.identifier.scopusid 2-s2.0-85067119149 -
dc.type.local Article(Overseas) -
dc.type.rims ART -
dc.description.journalClass 1 -
dc.contributor.nonIdAuthor Khan, lImran -
dc.contributor.nonIdAuthor Shukla, Shruti -
dc.contributor.nonIdAuthor Lee, Hoomin -
dc.contributor.nonIdAuthor Oh, Mi-Wah -
dc.contributor.nonIdAuthor Bajpai, Vivek K. -
dc.contributor.nonIdAuthor Huh, Yun Suk -
dc.contributor.nonIdAuthor Kang, Sun Chul -
dc.identifier.citationVolume 181 -
dc.identifier.citationStartPage 612 -
dc.identifier.citationEndPage 622 -
dc.identifier.citationTitle Colloids and Surfaces B: Biointerfaces -
dc.type.journalArticle Article -
dc.description.isOpenAccess N -
dc.subject.keywordAuthor Carvacrol encapsulated nanoemulsion -
dc.subject.keywordAuthor Angiogenesis -
dc.subject.keywordAuthor A549 -
dc.subject.keywordAuthor In vivo -
dc.subject.keywordAuthor In silico -
dc.subject.keywordPlus NF-KAPPA-B -
dc.subject.keywordPlus NANOEMULSION -
dc.subject.keywordPlus ACTIVATION -
dc.subject.keywordPlus EXPRESSION -
dc.subject.keywordPlus DELIVERY -
dc.subject.keywordPlus THERAPY -
dc.subject.keywordPlus DOCKING -
dc.subject.keywordPlus TISSUE -
dc.subject.keywordPlus CELLS -
dc.subject.keywordPlus ERK -
Files in This Item:

There are no files associated with this item.

Appears in Collections:
ETC 1. Journal Articles

qrcode

  • twitter
  • facebook
  • mendeley

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE